<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39427144</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>19</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2458</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>19</Day></PubDate></JournalIssue><Title>BMC public health</Title><ISOAbbreviation>BMC Public Health</ISOAbbreviation></Journal><ArticleTitle>Frequency of exposure to Toxoplasma gondii in COVID-19 patients: a systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>2885</StartPage><MedlinePgn>2885</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2885</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12889-024-20334-x</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Toxoplasmosis is a chronic protozoan parasitic infection that affects nearly one-third of the global population. During the COVID-19 pandemic, cases were observed in patients with COVID-19 and toxoplasmosis. Therefore, this systematic review and meta-analysis aimed to determine the frequency of Toxoplasma gondii exposure in patients with COVID-19.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A literature search was conducted in six databases or search tools (PubMed, Scopus, Embase, Web of Science, ScienceDirect, and Google Scholar) until March 3, 2024. Study selection, quality assessment, and data extraction were performed independently by three investigators. Statistical analysis was performed using R version 4.3, applying a random-effects model. The quality of the included observational studies was assessed using the "JBI-MAStARI".</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 5,936 studies were retrieved, 13 of which were included in the final meta-analysis. The sample included a total of 2,947 patients with COVID-19 from four countries, of whom approximately 43.3% were men and 49.4% were women. Among the patients, 1,323 showed evidence of exposure to T. gondii through IgG detection, while 1,302 COVID-19 patients were explicitly examined for T. gondii by IgM detection, and 36 positive cases were identified. The frequency of exposure to T. gondii, determined by the presence of IgG in patients with COVID-19, reached 49% (95% CI: 34-63%; 2,947 participants; 13 studies; I<sup>2</sup> = 98%, p &lt; 0.01). In addition, the frequency of exposure to T. gondii, evaluated by IgM presence in patients with COVID-19, was 2% (95% CI: 0-6%; 1,302 participants; 6 studies; I<sup>2</sup> = 94%, p &lt; 0.01).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">It was shown that almost half of COVID-19 patients had previous exposure to T. gondii through the presence of IgG, and a small percentage, 2%, showed active infection through IgM detection. Although the results indicate a possible correlation between exposure to T. gondii and the presence of COVID-19, it is essential to note that this study is based on observational research, which precludes establishing a causal relationship. Consequently, further research is required to deepen understanding of the interaction between the two conditions.</AbstractText><AbstractText Label="TERMS USED" NlmCategory="UNASSIGNED">The Joanna Briggs Institute Meta-Analysis of Statistics Assessment and Review Instrument (JBI-MAStARI), Prospective International Registry of Systematic Reviews (PROSPERO), and Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>León-Figueroa</LastName><ForeName>Darwin A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Facultad de Medicina Humana, Universidad de San Martín de Porres, Chiclayo, 14012, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barboza</LastName><ForeName>Joshuan J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Universidad Peruana de Ciencias Aplicadas, Lima, 15023, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siddiq</LastName><ForeName>Abdelmonem</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Faculty of Pharmacy, Mansoura University, Mansoura, 35516, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aguirre-Milachay</LastName><ForeName>Edwin</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Facultad de Medicina Humana, Universidad de San Martín de Porres, Chiclayo, 14012, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quispe-Vicuña</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Unidad de Revisiones Sistemáticas y Meta-Análisis, Tau-Relaped Group, Trujillo, 13001, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sah</LastName><ForeName>Ranjit</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Tribhuvan University Teaching Hospital, Institute of Medicine, Kathmandu, 44600, Nepal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Microbiology, Dr. D. Y. Patil Medical College, Hospital and Research Centre, Dr. D. Y. Patil Vidyapeeth, Pune, Maharashtra, 411018, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Public Health Dentistry, Dr. D.Y. Patil Dental College and Hospital, Dr. D.Y. Patil Vidyapeeth, Pune, Maharashtra, 411018, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valladares-Garrido</LastName><ForeName>Mario J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Universidad Continental, Lima, 15046, Peru. mvalladares@continental.edu.pe.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Oficina de Inteligencia Sanitaria, Red Prestacional EsSalud Lambayeque, Chiclayo, 14008, Peru. mvalladares@continental.edu.pe.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adhikari</LastName><ForeName>Suraj</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Manipal College of Medical Sciences, Pokhara, Nepal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonilla-Aldana</LastName><ForeName>D Katterine</ForeName><Initials>DK</Initials><AffiliationInfo><Affiliation>College of Medicine, Korea University, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ricardo-Martínez</LastName><ForeName>Alex</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Universidad Peruana de Ciencias Aplicadas, Lima, 15023, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morales-Ramos</LastName><ForeName>Jorge Guillermo</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Escuela de Medicina Humana, Universidad Señor de Sipán, Chiclayo, 14001, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodriguez-Morales</LastName><ForeName>Alfonso J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Master of Clinical Epidemiology and Biostatistics, Universidad Cientifica del Sur, Lima, 15067, Peru.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gilbert and Rose-Marie Chagoury School of Medicine, Lebanese American University, Beirut, 1102, Lebanon.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Public Health</MedlineTA><NlmUniqueID>100968562</NlmUniqueID><ISSNLinking>1471-2458</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014123" MajorTopicYN="Y">Toxoplasmosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014122" MajorTopicYN="Y">Toxoplasma</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">T. gondii</Keyword><Keyword MajorTopicYN="N">Toxoplasma gondii</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Epidemiology</Keyword><Keyword MajorTopicYN="N">Toxoplasmosis</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>20</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>20</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>19</Day><Hour>23</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39427144</ArticleId><ArticleId IdType="pmc">PMC11490129</ArticleId><ArticleId IdType="doi">10.1186/s12889-024-20334-x</ArticleId><ArticleId IdType="pii">10.1186/s12889-024-20334-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mallah SI, Ghorab OK, Al-Salmi S, Abdellatif OS, Tharmaratnam T, Iskandar MA, et al. COVID-19: breaking down a global health crisis. Ann Clin Microbiol Antimicrob. 2021;20(1):35. 10.1186/s12941-021-00438-7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8129964</ArticleId><ArticleId IdType="pubmed">34006330</ArticleId></ArticleIdList></Reference><Reference><Citation>León-Figueroa DA, Abanto-Urbano S, Olarte-Durand M, Nuñez-Lupaca JN, Barboza JJ, Bonilla-Aldana DK, et al. COVID-19 and dengue coinfection in Latin America: a systematic review. New Microbes New Infect. 2022;49:101041. 10.1016/j.nmni.2022.101041.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9613782</ArticleId><ArticleId IdType="pubmed">36320316</ArticleId></ArticleIdList></Reference><Reference><Citation>Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a systematic review and meta-analysis. J Infect. 2020;81(2):266–75. 10.1016/j.jinf.2020.05.046.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7255350</ArticleId><ArticleId IdType="pubmed">32473235</ArticleId></ArticleIdList></Reference><Reference><Citation>Prevention, CC for DC and. CDC - Toxoplasmosis - Epidemiology &amp; Risk Factors [Internet]. 2019. Available online: https://www.cdc.gov/parasites/toxoplasmosis/epi.html (accessed on 21 May 2023).</Citation></Reference><Reference><Citation>Molan A, Nosaka K, Hunter M, Wang W. Global status of Toxoplasma gondii infection: systematic review and prevalence snapshots. Trop Biomed. 2019;36(4):898–925.</Citation><ArticleIdList><ArticleId IdType="pubmed">33597463</ArticleId></ArticleIdList></Reference><Reference><Citation>Rostami A, Riahi SM, Gamble HR, Fakhri Y, Nourollahpour Shiadeh M, Danesh M, et al. Global prevalence of latent toxoplasmosis in pregnant women: a systematic review and meta-analysis. Clin Microbiol Infect. 2020;26(6):673–83. 10.1016/j.cmi.2020.01.008.</Citation><ArticleIdList><ArticleId IdType="pubmed">31972316</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubey JP. Outbreaks of clinical toxoplasmosis in humans: five decades of personal experience, perspectives and lessons learned. Parasit Vectors. 2021;14(1):263. 10.1186/s13071-021-04769-4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8136135</ArticleId><ArticleId IdType="pubmed">34011387</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowiak Ł, Rozsa L, Tryjanowski P, Møller AP. A negative covariation between toxoplasmosis and CoVID-19 with alternative interpretations. Sci Rep. 2020;10(1):12512. 10.1038/s41598-020-69351-x.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7385593</ArticleId><ArticleId IdType="pubmed">32719490</ArticleId></ArticleIdList></Reference><Reference><Citation>Galván-Ramírez M, de la Salas-Lais L, Muñoz-Medina AG, Fernandes-Matano JE, Pérez L. Franco De León K. Association of Toxoplasmosis and COVID-19 in a Mexican Population. Microorganisms. 2023;11(6):1441. 10.3390/microorganisms11061441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10305166</ArticleId><ArticleId IdType="pubmed">37374943</ArticleId></ArticleIdList></Reference><Reference><Citation>Yarovinsky F. Innate immunity to Toxoplasma Gondii infection. Nat Rev Immunol. 2014;14(2):109–21. 10.1038/nri3598.</Citation><ArticleIdList><ArticleId IdType="pubmed">24457485</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdel-Hamed EF, Ibrahim MN, Mostafa NE, Moawad HSF, Elgammal NE, Darwiesh EM, et al. Role of interferon gamma in SARS-CoV-2-positive patients with parasitic infections. Gut Pathog. 2021;13(1):29. 10.1186/s13099-021-00427-3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8096133</ArticleId><ArticleId IdType="pubmed">33947467</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharaf-El-Deen SA. Toxoplasma Gondii as a possible risk factor for COVID-19 severity: a case-control study. Egypt J Med Microbiol. 2021;30(2):125–32.</Citation></Reference><Reference><Citation>Ghaffari S, Kalantari N, Gorgani-Firouzjaee T, Bayani M, Jalali F, Daroonkola MA. Is COVID-19 associated with latent toxoplasmosis? Environ Sci Pollut Res Int diciembre de. 2021;28(47):67886–90. 10.1007/s11356-021-17126-w.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8542425</ArticleId><ArticleId IdType="pubmed">34693492</ArticleId></ArticleIdList></Reference><Reference><Citation>Halawi M, Al-Hazmi A, Aljuaid A, Allahyani M, Abdulaziz O, Almalki A. Seroprevalence of Toxoplasma Gondii, Rubella, Group A Streptococcus, CMV and HSV-1 in COVID-19 patients with Vitamin D Deficiency. Pak J Biol Sci PJBS. 2021;24(11):1169–74. 10.3923/pjbs.2021.1169.1174.</Citation><ArticleIdList><ArticleId IdType="pubmed">34842389</ArticleId></ArticleIdList></Reference><Reference><Citation>Geraili A, Badirzadeh A, Sadeghi M, Mousavi SM, Mousavi P, Shahmoradi Z, et al. Toxoplasmosis and symptoms severity in patients with COVID-19 in referral centers in Northern Iran. J Parasit Dis off Organ Indian Soc Parasitol. 2022;47(1):1–7. 10.1007/s12639-022-01556-5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9741704</ArticleId><ArticleId IdType="pubmed">36532601</ArticleId></ArticleIdList></Reference><Reference><Citation>Montazeri M, Nakhaei M, Fakhar M, Pazoki H, Pagheh AS, Nazar E, et al. Exploring the Association between Latent Toxoplasma Gondii Infection and COVID-19 in hospitalized patients: First Registry-based study. Acta Parasitol. 2022;67(3):1172–9. 10.1007/s11686-022-00559-9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9094600</ArticleId><ArticleId IdType="pubmed">35545737</ArticleId></ArticleIdList></Reference><Reference><Citation>Habib S, Hamza E, El-Gamal R, Nosser NA, Aboukamar WA, Abdelsalam S, et al. Clinical and immunological impacts of latent toxoplasmosis on COVID-19 patients. Cureus. 2023;15(9):e45989. 10.7759/cureus.45989.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10601516</ArticleId><ArticleId IdType="pubmed">37900421</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahmoudi MR, Saadat F, Yaghubi Kalurazi T, Ali Verdiloo F, Karanis P. Latent toxoplasmosis in COVID-19 patients and link with higher mortality in COVID-19 male patients. Microb Pathog. 2023;185:106402. 10.1016/j.micpath.2023.106402.</Citation><ArticleIdList><ArticleId IdType="pubmed">37866548</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouda MA, AboShabaan HS, Abdelgawad AS, Abdel Wahed AS, Abd El-Razik A, Elsaadawy K. Association between breakthrough infection with COVID-19 and Toxoplasma Gondii: a cross-sectional study. Sci Rep. 2023;13(1):17636. 10.1038/s41598-023-44616-3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10582182</ArticleId><ArticleId IdType="pubmed">37848511</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouda MA, Aboshabaan HS, Abdelgawad AS, Wahed ASA, Ibrahim AF. TOXOPLASMOSIS IN VACCINATED COVID-19 PATIENTS. J Egypt Soc Parasitol. 2023;53(2):381–6. 10.21608/jesp.2023.312186.</Citation></Reference><Reference><Citation>Hasanzadeh M, Ahmadpour E, Mahami-Oskouei M, Musavi S, Parsaei M, Sarafraz N, et al. Genetic diversity and seroprevalence of Toxoplasma Gondii in COVID–19 patients; a first case-control study in Iran. BMC Infect Dis. 2024;24(1):42. 10.1186/s12879-023-08964-9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10763165</ArticleId><ArticleId IdType="pubmed">38172676</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdeltawab MSA, Fateen M, Saad El-Din S, Elmessiery RM, Mohammady Mohamed O, Marzouk Sadek K, et al. Effect of SARS-CoV-2 and Toxoplasma Gondii co-infection on IFN-γ and TNF-α expression and its impact on disease severity. Cytokine. 2024;177:156545. 10.1016/j.cyto.2024.156545.</Citation><ArticleIdList><ArticleId IdType="pubmed">38368695</ArticleId></ArticleIdList></Reference><Reference><Citation>Nemati Zargaran F, Rostamian M, Kooti S, Madanchi H, Ghadiri K. Co-infection of COVID-19 and parasitic diseases: a systematic review. Parasite Epidemiol Control. 2023;21:e00299. 10.1016/j.parepi.2023.e00299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10062795</ArticleId><ArticleId IdType="pubmed">37091061</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Qushayri AE, Reda A, Shah J. COVID-19 and monkeypox co-infection: a rapid systematic review. Front Immunol. 2022;13:1094346. 10.3389/fimmu.2022.1094346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9794570</ArticleId><ArticleId IdType="pubmed">36591217</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Morales AJ, León-Figueroa DA, Sah R, Villamil-Gomez WE. Arboviral diseases and monkeypox – an epidemiological overlapping differential diagnosis? Rev Cuerpo Méd Hosp Nac Almanzor Aguinaga Asenjo. 2022;15(3):323–4. 10.35434/rcmhnaaa.2022.153.1678.</Citation></Reference><Reference><Citation>Wilairatana P, Masangkay FR, Kotepui KU, Milanez GDJ, Kotepui M. Prevalence and characteristics of malaria among COVID-19 individuals: a systematic review, meta-analysis, and analysis of case reports. PLoS Negl Trop Dis. 2021;15(10):e0009766. 10.1371/journal.pntd.0009766.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8486116</ArticleId><ArticleId IdType="pubmed">34597315</ArticleId></ArticleIdList></Reference><Reference><Citation>Martins-Melo FR, Castro MC, Ribeiro ALP, Heukelbach J, Werneck GL. Deaths related to Chagas Disease and COVID-19 Co-infection, Brazil, March-December 2020. Emerg Infect Dis. 2022;28(11):2285–9. 10.3201/eid2811.212158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9622242</ArticleId><ArticleId IdType="pubmed">36170771</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Morales AJ, Romaní L, León-Figueroa DA. COVID-19 and Chagas disease in Latin America. Rev Cuerpo Méd Hosp Nac Almanzor Aguinaga Asenjo. 2022;15(2):171–3. 10.35434/rcmhnaaa.2022.152.1499.</Citation></Reference><Reference><Citation>Baker RE, Mahmud AS, Miller IF, Rajeev M, Rasambainarivo F, Rice BL, et al. Infectious disease in an era of global change. Nat Rev Microbiol. 2022;20(4):193–205. 10.1038/s41579-021-00639-z.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8513385</ArticleId><ArticleId IdType="pubmed">34646006</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitlik SD. COVID-19 compared to other Pandemic diseases. Rambam Maimonides Med J. 2020;11(3):e0027. 10.5041/RMMJ.10418.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7426550</ArticleId><ArticleId IdType="pubmed">32792043</ArticleId></ArticleIdList></Reference><Reference><Citation>Flegr J. Toxoplasmosis is a risk factor for acquiring SARS-CoV-2 infection and a severe course of COVID-19 in the Czech and Slovak population: a preregistered exploratory internet cross-sectional study. Parasit Vectors. 2021;14(1):508. 10.1186/s13071-021-05021-9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8477627</ArticleId><ArticleId IdType="pubmed">34583758</ArticleId></ArticleIdList></Reference><Reference><Citation>Windle M, Lee HD, Cherng ST, Lesko CR, Hanrahan C, Jackson JW, et al. From epidemiologic knowledge to Improved Health: a vision for translational epidemiology. Am J Epidemiol. 2019;188(12):2049–60. 10.1093/aje/kwz085.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8045479</ArticleId><ArticleId IdType="pubmed">30927354</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayouni I, Maatoug J, Dhouib W, Zammit N, Fredj SB, Ghammam R, et al. Effective public health measures to mitigate the spread of COVID-19: a systematic review. BMC Public Health. 2021;21(1):1015. 10.1186/s12889-021-11111-1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8164261</ArticleId><ArticleId IdType="pubmed">34051769</ArticleId></ArticleIdList></Reference><Reference><Citation>Ros F, Kush R, Friedman C, Gil Zorzo E, Rivero Corte P, Rubin JC, et al. Addressing the Covid-19 pandemic and future public health challenges through global collaboration and a data-driven systems approach. Learn Health Syst. 2021;5(1):e10253. 10.1002/lrh2.10253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7744897</ArticleId><ArticleId IdType="pubmed">33349796</ArticleId></ArticleIdList></Reference><Reference><Citation>Haldane V, Jung AS, De Foo C, Bonk M, Jamieson M, Wu S, et al. Strengthening the basics: public health responses to prevent the next pandemic. BMJ. 2021;375:e067510. 10.1136/bmj-2021-067510.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8624065</ArticleId><ArticleId IdType="pubmed">34840134</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguirre AA, Longcore T, Barbieri M, Dabritz H, Hill D, Klein PN, et al. The One Health Approach to Toxoplasmosis: Epidemiology, Control, and Prevention Strategies. EcoHealth. 2019;16(2):378–90. 10.1007/s10393-019-01405-7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6682582</ArticleId><ArticleId IdType="pubmed">30945159</ArticleId></ArticleIdList></Reference><Reference><Citation>Roe K. The role of polyspecific T-cell exhaustion in severe outcomes for COVID-19 patients having latent pathogen infections such as Toxoplasmagondii. Microb Pathog. 2021;161(Pt B):105299. 10.1016/j.micpath.2021.105299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8605814</ArticleId><ArticleId IdType="pubmed">34813900</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>